Clinical Failure and Emergence of Resistance during Third Generation Cephalosporin Therapy for Enterobacter spp. Infection: Is the Risk Overestimated? A Prospective Multicentric Study

Background: Clinical and microbiological guidelines recommend treating infections caused by Enterobacter spp. with cefepime or carbapenems. The main objective of this study was to assess the risk clinical failure third generation cephalosporin (3GC) therapy compared other β-lactams for Our secondary evaluate emergence resistance during therapy. Methods: We conducted a prospective observational in seven French hospitals over an 18-month period including all patients pulmonary and/or bloodstream infection due susceptible 3GC. Results: Seventy-four were included our study. Among them, 26 (35%) received 3GC as first-line treatment, improvements observed 13/21 (62%) them. Four (5%) cases one group. can be safely used especially non-severe suffering from Conclusions: Emergence remains rare event, there is lack evidence benefit last-line antibiotics therapies.